Thymosin Alpha-1
ExperimentalThymic peptide / approved outside USExperimental
28-aa thymic peptide (thymalfasin). Approved in several countries (Zadaxin) for hepatitis B and as an immune adjuvant; not FDA-approved in the US.
For research use only.
Key Facts
- CAS
- 62304-98-7
- Molecular Weight (MW)
- 3108.3 g/mol
- Half-life
- ~2 hours
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Daily or 2-3x weekly
- Last updated
- 8/23/2026
- Targets
- T cellsInnate immune receptors
Overview
28-aa thymic peptide (thymalfasin). Approved in several countries (Zadaxin) for hepatitis B and as an immune adjuvant; not FDA-approved in the US.
Protocol
- Dosage Range
- 300-900 mcg daily or 1.6 mg 2-3x weekly
- Frequency
- Daily or 2-3x weekly
- Cycle
- 4-24 weeks on, 4-6 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 3 mL BAC for 5 mg vial
Science
Mechanism of Action
Enhances T-cell and dendritic-cell function and TLR signaling in infection and vaccine-adjuvant studies.
Targets
T cellsInnate immune receptors
Studies
- Thymosin alpha-1 immune reviewโ Journal/year not available
Benefits
International immune-therapy literature
Potential Side Effects
- Injection-site reactions
- Flu-like symptoms
References
- PMID 22051118External link ยท Year โ